Cardiovascular effects of endogenous and exogenous sex hormones over a woman's lifetime

American Journal of Obstetrics and Gynecology

Volumn 158, Issue 6, 1988, Pages 1630-1643

  Knopp, Robert H ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

cardiovascular disease in women; Cardiovascular effects; endogenous vs exogenous sex hormones

Indexed keywords

CHOLESTEROL; ESTROGEN; GESTAGEN; LIPOPROTEIN; ORAL CONTRACEPTIVE AGENT; PROGESTERONE;

CARDIOVASCULAR DISEASE; FEMALE; HUMAN; PRIORITY JOURNAL; REVIEW;

ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; CONTRACEPTIVES, ORAL, HORMONAL; DRUG INTERACTIONS; ESTROGENS; EVALUATION STUDIES; FEMALE; HUMAN; LIPOPROTEINS; LIPOPROTEINS, HDL CHOLESTEROL; LIPOPROTEINS, LDL CHOLESTEROL; MALE; MENOPAUSE; MENSTRUAL CYCLE; PREGNANCY; PROGESTERONE; PUBERTY; RISK FACTORS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0023933007     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9378(88)90201-3     Document Type: Article

References (85)

1. Arteriosclerosis risk: the roles of oral contraceptives and postmenopausal estrogens
2. The effects of oral contraceptive use on lipoproteins: significance for atherosclerosis
3. Arteriosclerosis risk in women and the role of oral contraceptives and postmenopausal estrogens
4. How LDL receptors influence cholesterol and atherosclerosis
5. A receptor-mediated pathway for cholesterol homeostasis
6. Female steroid hormones and lipoprotein synthesis in the cockerel: effects of progesterone and nafoxidine on the estrogenic stimulation of very low density lipoproteins (VLDL) synthesis
7. The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females
8. Pharmacologically induced hypolipidemia
9. Effects of 17 alpha-ethinyl estradiol on the serum lipoproteins of cholesterol fed diabetic rats
10. Autoradiographic localization of the sites of uptake, cellular transport, and catabolism of low density lipoproteins in the liver of normal and estrogen treated rats
11. Increased binding of low density lipoproteins to liver membranes from rats treated with 17 alpha-ethinyl estradiol
12. Increased mRNA for low density lipoprotein receptor in livers of rabbits treated with 17 alpha-ethinyl estradiol
13. Effect of estrogen on post-heparin lipolytic activity: selective decline in hepatic triglyceride lipase
14. Biliary lipids, bile acids, and gall bladder function in the human female: effects of pregnancy and the ovulatory cycle
15. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency
16. Comparative studies of the ethinyl estrogens used in oral contraceptives. VII. Effects with and without progestational agents on ultracentrifugally fractionated plasma lipoproteins in humans, baboons, and beagles
17. Effects of oral contraceptives on lipoproteins
18. Norethindrone acetate inhibition of splanchnic triglyceride secretion in conscious glucosefed swine
19. Sex steroid influence on triglyceride metabolism
20. The effects of 17 beta-estradiol and progesterone on the metabolism of free fatty acid by perfused livers from normal female and ovariectamized rats
21. Divergent effects of d-norgeitrel on the metabolism of rat very low density and low density apolipoprotein B
22. Regulation of hepatic lipase and serum lipoproteins by sex steroids
23. Serum high-density lipoprotein cholesterol in women using oral contraceptives, estrogens and progestin
24. Progestogens and lipid metabolism
25. Studies on the metabolic mechanism of reduced high-density lipoproteins during anabolic steroid therapy
26. Contraceptive steroids increase hepatic uptake of chylomicron remnants in healthy young women
27. Effects of estrogen/progestin agents on plasma retinoids and chylomicron remnant metabolism
28. Type III hyperlipoproteinemia (“remnant removal disease”). Insight into the pathogenetic mechanism
29. Decrease in plasma high-density lipoprotein cholesterol levels at puberty in boys with delayed adolescence
30. High and low density lipoprotein cholesterols in adolescent boys: relationships with endogenous te tosterone, estradiol, and quetelet index
31. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary disease
32. Relation of serum lipoproteins and systolic blood pressure to early atherosclerosis: the Bogalusa Heart Study
33. Serum cholesterol, lipoproteins, and the risk of coronary disease: the Framingham Study
34. Studies of hypercholesterolemia in the nonhuman primate. I. Changes that lead to fatty streak formation
35. Studies of hypercholesterolemia in the nonhuman primate. II. Fatty streak conversion to fibrous plaque
36. The pathogenesis of atherosclerosis
37. Fluctuations in human lipoproteins during the normal menstrual cycle
38. Changes in lipoprotein composition during the menstrual cycle
39. Estradiol, progesterone, and plasma lipids during the menstrual cycle
40. Lipid composition of serum lipoproteins in relation to gonadal hormone during the normal menstrual cycle
41. Variations in serum lipids and lipoproteins throughout the menstrual cycle
42. Variation of postheparin plasma hepatic lipase by menstrual cycle
43. Effect of menstrual cycle phase on plasma lipids
44. 24-hour energy expenditure and the menstrual cycle
45. Plasma lipo-proteins including high density lipoprotein subfractions during normal pregnancy
46. Correlation of hormones with lipid and lipoprotein levels during normal pregnancy and postpartum
47. Lipoprotein metabolism in pregnancy, fat transport to the fetus, and the effects of diabetes
48. Relationships of infant birth size to maternal lipoproteins, apoprotein, fuel, hormones, clinical chemistries and body weight at 36 weeks gestation
49. Number of pregnancies, use of oral contraceptives and menopausal age in women with ischaemic heart disease, compared to a population sample of women
50. Intraindividual changes of blood pressure, serum lipids, and body weight in relation to menstrual status: results from a prospective population study of women in Goteborg, Sweden
51. The prevalence and correlates of Rose Questionnaire angina among women and men in the Lipid Research Clinic's Program Prevalence Study population
52. Ischaemic heart disease in young women
53. Effect of estrogen/progestin potency on lipid-lipoprotein cholesterol
54. Progestins and oral contraceptive-induced lipoprotein changes: a prospective study
55. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-μg oestrogen preparations
56. Progestogens and arterial disease: evidence from the Royal College of General Practitioners' study
57. Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives
58. Coronary atherosclerosis and myocardial infarction in young women: role of oral contraceptives
59. Concerning the pathology of acute coronary heart disease in young women
60. The effect of progestins in combined oral contraceptives on serum lipids with special reference to high-density lipoproteins
61. Effects of two low-dose oral contraceptives on serum lipids and lipoproteins: differential changes in high-density lipoprotein subclasses
62. Lipid and lipoprotein changes associated with oral contraceptive use: a randomized clinical trial
63. A randomized crossover comparison of two low-dose contraceptives: effects on serum lipids and lipoproteins
64. Effects of estrogens and progestins in high-density lipoproteins
65. Comparative effects of monophasic desogestrel plus ethinyloestradiol and triphasic levonorgestrel plus ethinyloestradiol on lipid metabolism
66. The effect of triphasic and biphasic oral contraceptive preparations on HDL cholesterol and LDL cholesterol in young women
67. Lipidemic changes induced by two different oral contraceptive formulations
68. Lipid, carbohydrate, and androgen metabolism in women using a triphasic oral contraceptive containing norethindrone for one year
69. Natural oestrogen as an effective treatment for type-II hyperlipoproteinemia in postmenopausal women
70. Comparison of lipid and androgen levels after conjugated estrogen or depomedroxyprogesterone acetate treatment in postmenopausal women
71. High-density lipoprotein subfractions during oral and cutaneous administration of 17-estradiol to menopausal women
72. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50
73. A prospective study of postmenopausal estrogen therapy and coronary heart disease
74. Coronary heart disease and its risk factors among women in the Framingham Study
75. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinic's Program Follow-up Study
76. Estrogen use and all cause mortality
77. Pregnancy associated inhibition of coronary artery atherosclerosis in monkeys
78. Contraceptive steroids and coronary artery atherosclerosis in cynomologous macaques
79. Changes in plasma lipids and lipoproteins in Macaca neuestrina during pregnancy and the postpartum period
80. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy
81. Oral progesterone and estrogen/progestogen therapy: effects of natural and synthetic hormones on subfractions of HDL cholesterol and liver proteins
82. Longterm effects of percutaneous estrogens and oral progesterone on serum lipoproteins in menopausal women
83. Efficacy of a continuous estrogen-progestin regimen in the menopausal patient